SEC
SlamSEC
SearchBrowseEarnings

Ultragenyx Pharmaceutical Inc.

Nasdaq:RARE
Pharmaceutical Preparations·NOVATO, CA
OverviewAll FilingsSum FinCreditInsidersGovernance
OverviewAll FilingsSum FinCreditInsidersGovernance

All Filings(1001 total)

TypeDateAccessionPeriodSize
144
Mar 6, 2026
0001950047-26-002334
—
5.7 KB
4
Mar 3, 2026
0001193125-26-0892874
Mar 1, 2026
7.0 KB
4
Mar 3, 2026
0001193125-26-0892824
Mar 1, 2026
6.9 KB
4
Mar 3, 2026
0001193125-26-0892784
Mar 1, 2026
7.6 KB
4
Mar 3, 2026
0001193125-26-0891114
Mar 1, 2026
6.9 KB
4
Mar 3, 2026
0001193125-26-0891094
Mar 2, 2026
6.7 KB
4
Mar 3, 2026
0001193125-26-0891074
Mar 1, 2026
9.4 KB
4
Mar 3, 2026
0001193125-26-0891044
Mar 1, 2026
6.9 KB
4
Mar 3, 2026
0001193125-26-0891024
Mar 1, 2026
6.3 KB
144
Mar 3, 2026
0001950047-26-002108
—
8.5 KB
144
Mar 2, 2026
0001950047-26-002038
—
7.2 KB
8-K
Feb 23, 2026
0001193125-26-0625688-K
Feb 23, 2026
149.7 KB
10-K
Feb 18, 2026
0001193125-26-05732910-K
Dec 31, 2025
19.0 MB
8-K
Feb 12, 2026
0001193125-26-0487388-K
Feb 12, 2026
553.2 KB
SCHEDULE 13G/A
Feb 5, 2026
0000315066-26-000545
—
11.1 KB
4
Feb 3, 2026
0001193125-26-0348324
Feb 2, 2026
4.5 KB
8-K
Feb 3, 2026
0001193125-26-0344748-K
Feb 3, 2026
170.0 KB
144
Feb 2, 2026
0001950047-26-000800
—
6.5 KB
8-K
Jan 30, 2026
0001193125-26-0305908-K
Jan 30, 2026
151.6 KB
8-K
Jan 12, 2026
0001193125-26-0097918-K
Jan 12, 2026
222.0 KB
4
Jan 5, 2026
0001193125-26-0024104
Jan 2, 2026
4.5 KB
144
Jan 2, 2026
0001950047-26-000020
—
6.5 KB
8-K
Dec 30, 2025
0001193125-25-3370998-K
Dec 30, 2025
149.7 KB
4
Dec 30, 2025
0001193125-25-3366194
Dec 29, 2025
4.9 KB
8-K
Dec 29, 2025
0001193125-25-3324228-K
Dec 29, 2025
154.3 KB
25 filings shown

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need.